Long-term results after resection for bone sarcoma pulmonary metastases
Carlos E. García Franco (a), Wenceslao Torre (a), Akiko Tamura (a), Francisco Guillén-Grima (b), Mikel San-Julian (c), Salvador Martin-Algarra (d) and Francisco J. Pardo (e)
(a) Department of General Thoracic Surgery, Clinica Universidad de Navarra, Pamplona, Spain
(b) Department of Preventive Medicine, Clinica Universidad de Navarra, Pamplona, Spain
(c) Department of Orthopedic Surgery, Clinica Universidad de Navarra, Pamplona, Spain
(d) Department of Medical Oncology, Clinica Universidad de Navarra, Pamplona, Spain
(e) Department of Pathology, Clinica Universidad de Navarra, Pamplona, Spain
Revista: European Journal of Cardio-Thoracic Surgery
Fecha: 01/05/2010Medicina Preventiva Cirugía Ortopédica y Traumatología Cirugía Torácica Anatomía Patológica Oncología Médica
Pulmonary metastases from bone sarcomas occur in approximately 40% of the cases. The combination of both chemotherapy and surgical resection is currently the standard treatment options for these patients. We aim to study the influence of different prognostic factors on long-term survival.
We reviewed the prognostic factors and survival rate in 52 consecutive patients with pulmonary metastases from bone sarcomas. All of them were previously treated with chemotherapy and submitted to metastasectomy at our institution from 1996 to 2006. Clinical and demographic variables, related to the primary tumour as well as to the pulmonary metastases, and treatment procedures were registered. Univariate (log-rank) and multivariate (Cox regression) analysis were carried out to identify significant prognostic factors related to overall survival. Five-year survival rates were estimated using Kaplan-Meier methods.
Median follow-up was 28 months. Follow-up duration ranged 7-148 months; the median survival was 27 months. As many as 31% of the patients were alive without disease, 3% were alive with disease, 64% died of disease while 2% died from other causes. Complete resection was achieved in 49 cases (94%). The overall 3- and 5-year survival rates were 43% and 31%, respectively. Univariate analysis showed (1) disease-free interval between treatment of the primary bone tumour and first lung metastasectomy (DFI) and (2) disease-free interval between first and second lung surgery (DFI2) as prognostic factors. Gender, primary site, histology of primary tumour, surgical approach, number of lung nodules, type of lung resection and re-do lung surgery did not have a significant impact on survival.
The long-term survival after bone sarcoma lung metastasectomy is encouraging. In our series, DFI and DFI2 were identified as the only prognostic factors.
CITA DEL ARTÍCULO Eur J Cardiothorac Surg. 2010 May;37(5):1205-8
tal vezLE INTERESE
La Clínica es el hospital privado con mayor dotación tecnológica de España, todo en un único centro.
Los profesionales de la Clínica realizan una labor continuada de investigación y formación, siempre en beneficio del paciente.
Conozca por qué somos diferentes a otros centros sanitarios. Calidad, rapidez, comodidad y resultados.